Trending Topics


Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator

Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact
Thursday, March 23, 2017
Leptomeningeal metastasis, cancer that has spread to the areas surrounding the brain and spinal cord, has long been a formidable clinical challenge for oncologists. Researchers at Memorial Sloan Kettering Cancer Center have identified the molecular basis of this increasingly prevalent complication of cancer. With the help of a mouse model, researchers have identified a drug strategy that may combat this virtually untreatable condition. This research by Joan Massagué, PhD, Adrienne Boire, MD, PhD, and colleagues, was published in the March 9, 2017 issue of Cell. For more information on this work and to speak with the study authors, contact
Thursday, March 9, 2017
Breast cancer affects one in eight women in the United States, with approximately 70 to 80 percent of employed breast cancer survivors returning to work three to eighteen months following diagnosis. Job loss can have devastating financial consequences, including increased risk of bankruptcy and debt. Victoria Blinder, MD, medical oncologist at Memorial Sloan Kettering, conducted a longitudinal study of a racially and ethnically diverse sample of employed women undergoing treatment for stage I-III breast cancer in New York City. For more information on this study, published in Health Affairs on February 6, 2017, and to speak with the study author, contact
Tuesday, February 7, 2017
See all trending topics

Press Releases

Jeffrey A. Drebin, MD, PhD, has been named the new Chairman of the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Drebin brings to MSK decades of experience as a world-class surgical oncologist specializing in pancreaticobiliary, upper gastrointestinal and liver surgery. He joins MSK from the Perelman School of Medicine of the University of Pennsylvania (UPenn) where he was most recently the John Rhea Barton Professor and Chairman of the Department of Surgery. Dr. Drebin formally assumes his new role as Peter Scardino, MD, steps down as Chairman after ten years of visionary leadership.
Monday, February 27, 2017
MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don’t tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.
Wednesday, February 22, 2017
Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused February 9 issue of Cell, the article — “Implementing Genome-Driven Oncology” — presents a critically self-reflective but solutions-focused perspective on this approach to cancer treatment.
Thursday, February 9, 2017
See all press releases

On Our Blog

Researchers find an epigenetic role in how breast cancer tumors develop resistance to treatment.
Thursday, March 23, 2017
MSK gastroenterologist Robin Mendelsohn weighs in on the possible benefits and drawbacks of using aspirin to reduce the risk of colon and rectal cancer.
Tuesday, March 21, 2017
Learn how a patient’s intestinal bacteria may influence the risk of cancers such as leukemia or lymphoma returning after bone marrow transplantation.
Friday, March 17, 2017
See all blog posts

Media Coverage

President and CEO Craig Thompson was interviewed about Memorial Sloan Kettering’s partnership with Hackensack Meridian Health.  
Wednesday, December 28, 2016
Medical oncologist Jae Park discusses new research that looks at how CAR-T therapy is making progress in treating brain cancer. 
Wednesday, December 28, 2016
Medical oncologists Robert Motzer and Alexander Lesokhin were interviewed for a special feature in The New York Times about minorities and clinical trials. 
Friday, December 23, 2016
See all media coverage

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at

For Journalists

Jeanne D'Agostino
Director, Media and Public Relations
Emily O'Donnell
Senior Communications Associate, Department of Surgery
Courtney Nowak
Senior Media Relations Associate
Caitlin Hool
Senior Media Associate
Nicole H. McNamara
Senior Media Relations Associate
Rebecca Williams
Media Associate
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.
After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.


Get the latest information from our media staff on advances in research at MSK.

Newsletter Sign Up Unsubscribe